Titratable fixed‐ratio combination of basal insulin plus a glucagon‐like peptide‐1 receptor agonist: A novel, simplified alternative to premix insulin for type 2 diabetes

Fernando Gomez‐Peralta,Ebaa Al‐Ozairi,Edward B. Jude,Xiaoying Li,Julio Rosenstock

DOI: https://doi.org/10.1111/dom.14365

2021-03-31

Diabetes, Obesity and Metabolism

Abstract:Despite novel therapeutic options, many people with type 2 diabetes (T2D) do not achieve their HbA1c targets. Given the progressive nature of T2D, many individuals not controlled with oral therapy will require advancement to injectable therapy using either a glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA), recently recommended as a first option, or traditionally a basal insulin. However, premix insulins remain frequently used, either as initial injectable therapy or as intensification from basal insulin. Premix insulin injections can potentially provide significant glycemic improvements to basal insulin but at the expense of increased hypoglycemia and weight gain and the need for multiple daily doses, which may affect treatment adherence. Real‐world evidence suggests that glycemic control often remains suboptimal with premix insulins. Fixed‐ratio combinations (FRCs) of basal insulin and GLP‐1 RAs provide a novel alternative to premix insulin for therapy intensification. While no direct comparisons between premix insulins and FRCs are available, results from meta‐analyses suggest that FRCs may offer better HbA1c reductions, lower risk of hypoglycemia, and less weight gain compared with premix insulin in a simplified treatment regimen. A head‐to‐head trial of T2D treatment intensification with premix insulin and FRCs of basal insulin plus GLP‐1 RAs is currently in progress, which should help clarify outcomes for each treatment option. The current article discusses the unmet needs of people with T2D treated with premix insulin and provides evidence supporting FRCs of basal insulin and GLP‐1 RAs as an alternative treatment option.This article is protected by copyright. All rights reserved.